CBD booster for Tough-to-Treat psychosis? major trial underway
NCT ID NCT07326124
First seen Jan 11, 2026 · Last updated May 11, 2026 · Updated 16 times
Summary
This study tests whether adding cannabidiol (CBD) to the standard drug clozapine can improve symptoms in people with treatment-resistant psychosis. About 250 participants will receive either CBD or a placebo for 12 weeks, alongside their usual medication. The goal is to see if CBD makes clozapine work better and is safe to use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSYCHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Cambridgeshire and Peterborough NHS Foundation Trust
Cambridge, United Kingdom
-
Charité Universitätsmedizin
Berlin, Germany
-
Geha Mental Health Center
Petah Tikva, Israel
-
Hospital General Universitario Gregorio Marañón
Madrid, Spain
-
Hospital Universitario Virgen del Rocío
Seville, Spain
-
Ludwig-Maximilian-University Munich
Munich, Germany
-
National and Kapodistrian University of Athens
Athens, Greece
-
Oxford Health NHS Foundation Trust
Oxford, United Kingdom
-
Psychiatric University Hospital (PUK), Zurich
Zurich, Switzerland
-
Shalvata Mental Health Center
Hod HaSharon, Israel
-
Sheba Medical Centre
Ramat Gan, Israel
-
Stichting Amsterdam UMC
Amsterdam, Netherlands
-
University Hospital Cologne
Cologne, Germany
-
University of Campania 'Luigi Vanvitelli'
Naples, Italy
-
West London NHS Trust
London, United Kingdom
Conditions
Explore the condition pages connected to this study.